帕立骨化醇与西那卡塞对CKD患者甲状旁腺嗜酸细胞含量的不同影响
该研究分析4例正常人和27例因继发性甲旁亢行甲状旁腺切除术的CKD患者的甲状旁腺组织,比较帕立骨化醇和/或西那卡塞对嗜酸细胞含量的影响。结果显示西那卡塞显著增加嗜酸细胞含量,而帕立骨化醇不增加,提示钙敏感受体激活参与主细胞向嗜酸细胞转分化。
要点
- 西那卡塞治疗显著增加CKD患者甲状旁腺嗜酸细胞含量。
- 帕立骨化醇不显著增加嗜酸细胞含量,且与西那卡塞相比有显著差异。
- 钙敏感受体激活可能参与主细胞向嗜酸细胞转分化。
核心结论
- 西那卡塞显著增加甲状旁腺嗜酸细胞含量,帕立骨化醇不增加,两者对甲状旁腺组成的影响不同。
研究设计与样本
- 分析4例正常人和27例因继发性甲旁亢行甲状旁腺切除术的CKD患者的甲状旁腺组织。
- 术前治疗分组:未治疗7例,单用西那卡塞7例,单用帕立骨化醇8例,西那卡塞联合帕立骨化醇5例。
主要发现
- 嗜酸细胞面积占组织总面积均值:正常人1.03%,未治疗5.3%,西那卡塞26.7%,帕立骨化醇6.9%,联合治疗12.7%。
- 西那卡塞与未治疗相比有显著差异;帕立骨化醇与西那卡塞相比有显著差异,与未治疗相比无显著差异。
临床怎么用
- 两种常用甲旁亢治疗对甲状旁腺组成的影响不同,或可影响功能,评估新药时需考虑。
局限性
- 样本量小,为观察性分析,未报告统计学细节和混杂因素控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The parathyroid oxyphil cell content increases in patients with chronic kidney disease (CKD), and even more in patients treated with the calcimimetic cinacalcet and/or calcitriol for hyperparathyroidism. Oxyphil cells have significantly more calcium-sensing receptors than chief cells, suggesting that the calcium-sensing receptor and calcimimetics are involved in the transdifferentiation of a chief cell to an oxyphil cell type. Here, we compared the effect of the vitamin D analog paricalcitol (a less calcemic analog of calcitriol) and/or cinacalcet on the oxyphil cell content in patients with CKD to further investigate the genesis of these cells. Parathyroid tissue from four normal individuals and 27 patients with CKD who underwent parathyroidectomy for secondary hyperparathyroidism were analyzed. Prior to parathyroidectomy, patients had received the following treatment: seven with no treatment, seven with cinacalcet only, eight with paricalcitol only, or cinacalcet plus paricalcitol in five. Oxyphilic areas of parathyroid tissue, reported as the mean percent of total tissue area per patient, were normal, 1.03; no treatment, 5.3; cinacalcet, 26.7 (significant vs. no treatment); paricalcitol, 6.9 (significant vs. cinacalcet; not significant vs. no treatment); and cinacalcet plus paricalcitol, 12.7. Cinacalcet treatment leads to a significant increase in parathyroid oxyphil cell content but paricalcitol does not, reinforcing a role for the calcium-sensing receptor activation in the transdifferentiation of chief-to-oxyphil cell type. Thus, two conventional treatments for hyperparathyroidism have disparate effects on parathyroid composition, and perhaps function. This finding is provocative and may be useful when evaluating future drugs for hyperparathyroidism.
引用
- Ritter C, Miller B, Coyne DW, et al. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease. Kidney Int. 2017. PMID: 28750928. doi:10.1016/j.kint.2017.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。